Therapeutic potential of Toll-like receptor 9 activation

CpG motifs in bacterial DNA trigger direct B-cell activation

Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508

Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells

Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697

Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells

Hartmann, G., & Krieg, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.944 · Cited by 605

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., & Aguzzi, A. (2004) · Nature Medicine · doi:10.1038/nm987 · Cited by 449

DNA methylation landscapes: Provocative insights from epigenomics

Suzuki, M. M., & Bird, A. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2341 · Cited by 3,039

Aptamers as therapeutics

Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289

Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE

Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372

RNA therapeutics: beyond RNA interference and antisense oligonucleotides

Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152

Interferons at age 50: past, current and future impact on biomedicine

Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154

Targeting neoantigens to augment antitumour immunity

Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997

Macrophages in Tumor Microenvironments and the Progression of Tumors

Hao, N.-B., Lü, M.-H., Fan, Y.-H., Cao, Y.-L., Zhang, Z.-R., & Yang, S.-M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/948098 · Cited by 1,003

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869

Role of intestinal microbiota and metabolites on gut homeostasis and human diseases

Lin, L., & Zhang, J. (2017) · BMC Immunology · doi:10.1186/s12865-016-0187-3 · Cited by 731

Progress towards in Vivo Use of siRNAs

Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677

DNA nanotechnology from the test tube to the cell

Chen, Y.-J., Groves, B., Muscat, R. A., & Seelig, G. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.195 · Cited by 594

Nucleic acid recognition by the innate immune system

Barbalat, R., Ewald, S. E., Mouchess, M. L., & Barton, G. M. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101340 · Cited by 577

Exploiting the critical perioperative period to improve long-term cancer outcomes

Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487

Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection

Fernandez-Ruiz, D., Ng, W. Y., Holz, L. E., Ma, J. Z., Zaid, A., Wong, Y. C., Lau, L. S., Mollard, V., Cozijnsen, A., Collins, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.011 · Cited by 438

Microglia and Inflammation in Alzheimers Disease

Mandrekar-Colucci, S., & Landreth, G. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012071 · Cited by 421

Advancement of the emerging field of RNA nanotechnology

Jasinski, D., Haque, F., Binzel, D. W., & Guo, P. (2017) · ACS Nano · doi:10.1021/acsnano.6b05737 · Cited by 352

Formation of the Protein Corona: The Interface between Nanoparticles and the Immune System

Barbero, F., Russo, L., Vitali, M., Piella, J., Salvo, I., Borrajo, M. L., Busquets-Fité, M., Grandori, R., Bastús, N. G., Casals, E., et al. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.10.001 · Cited by 263

The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9–dependent innate immune responses in the liver

Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246

Induction of Toll-Like Receptor 9 Signaling as a Method for Ameliorating Alzheimer's Disease-Related Pathology

Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166

Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis

Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160

Microglia Activated with the Toll-Like Receptor 9 Ligand CpG Attenuate Oligomeric Amyloid β Neurotoxicity in in Vitro and in Vivo Models of Alzheimer’s Disease

Doi, Y., Mizuno, T., Maki, Y., Jin, S., Mizoguchi, H., Ikeyama, M., Doi, M., Michikawa, M., Takeuchi, H., & Suzumura, A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090418 · Cited by 135

CpG oligodeoxynucleotides as immunotherapy in cancer

Jahrsdörfer, B., & Weiner, G. J. (2008) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.11.003 · Cited by 132

Requirement for DNA CpG Content in TLR9-Dependent Dendritic Cell Activation Induced by DNA-Containing Immune Complexes

Yasuda, K., Richez, C., Uccellini, M. B., Richards, R. J., Bonegio, R. G., Akira, S., Monestier, M., Corley, R. B., Viglianti, G. A., Marshak-Rothstein, A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900399 · Cited by 118

Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation

Carvalho, A., Cunha, C., Carotti, A., Aloisi, T., Guarrera, O., Di Ianni, M., Falzetti, F., Bistoni, F., Aversa, F., Pitzurra, L., et al. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.06.004 · Cited by 104

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108

Activation of toll-like receptor signaling pathways leading to nitric oxide-mediated antiviral responses

Abdul-Cader, M. S., Amarasinghe, A., & Abdul-Careem, M. F. (2016) · Archives of Virology · doi:10.1007/s00705-016-2904-x · Cited by 99

Toll like receptors and viruses

Finberg, R. W., Wang, J. P., & Kurt‐Jones, E. A. (2007) · Reviews in Medical Virology · doi:10.1002/rmv.525 · Cited by 90

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts

Damiano, V., Caputo, R., Garofalo, S., Bianco, R., Rosa, R., Merola, G., Gelardi, T., Racioppi, L., Fontanini, G., De Placido, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705226104 · Cited by 71

The innate immune system in Alzheimer's disease

Boutajangout, A., & Wisniewski, T. (2013) · International Journal of Cell Biology · doi:10.1155/2013/576383 · Cited by 69

Toll-like receptor agonists: a patent review (2011 - 2013)

Hussein, W. M., Liu, T.-Y., Skwarczynski, M., & Toth, I. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.880691 · Cited by 68

Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation

Kartikasari, A. E. R., Prakash, M. D., Cox, M., Wilson, K., Boer, J. C., Cauchi, J. A., & Plebanski, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03109 · Cited by 54

Minimal Sequence Requirements for Oligodeoxyribonucleotides Activating Human TLR9

Pohar, J., Kužnik Krajnik, A., Jerala, R., & Benčina, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402755 · Cited by 55

Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K - Ras Mutant Colorectal and Pancreatic Cancers

Rosa, R., Melisi, D., Damiano, V., Bianco, R., Garofalo, S., Gelardi, T., Agrawal, S., Di Nicolantonio, F., Scarpa, A., Bardelli, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3376 · Cited by 54

CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils.

Spinner, D. S., Kascsak, R. B., LaFauci, G., Meeker, H. C., Ye, X., Flory, M. J., Kim, J. I., Schuller-Levis, G. B., Levis, W. R., Wisniewski, T., et al. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1106665 · Cited by 54

Proof of Concept: Pharmacological Preconditioning with a Toll-like Receptor Agonist Protects against Cerebrovascular Injury in a Primate Model of Stroke

Bahjat, F. R., Williams-Karnesky, R. L., Kohama, S. G., West, G. A., Doyle, K. P., Spector, M. D., Hobbs, T. R., & Stenzel-Poore, M. P. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.6 · Cited by 51

Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer’s disease pathology in aged squirrel monkeys

Patel, A. G., Nehete, P. N., Krivoshik, S. R., Pei, X., Cho, E. L., Nehete, B. P., Ramani, M. D., Shao, Y., Williams, L. E., Wisniewski, T., et al. (2021) · Brain · doi:10.1093/brain/awab129 · Cited by 44

Effects of oleanolic acid on inflammation and metabolism in diabetic rats

Iskender, H., Dokumacioglu, E., Terim Kapakin, K. A., Yenice, G., Mohtare, B., Bolat, I., & Hayirli, A. (2022) · Biotechnic & Histochemistry · doi:10.1080/10520295.2021.1954691 · Cited by 32

Intracellular PRRs Activation in Targeting the Immune Response Against Fungal Infections

Jannuzzi, G. P., de Almeida, J. R. F., Paulo, L. N. M., de Almeida, S. R., & Ferreira, K. S. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.591970 · Cited by 29

Natural Killer Cell-Dependent Anti-Fibrotic Pathway in Liver Injury via Toll-Like Receptor-9

Abu-Tair, L., Axelrod, J. H., Doron, S., Ovadya, Y., Krizhanovsky, V., Galun, E., Amer, J., & Safadi, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082571 · Cited by 28

Allergic rhinitis patients with recurrent acute sinusitis have increased sinonasal epithelial cell TLR9 expression

Melvin, T. N., Lane, A. P., Nguyen, M., & Lin, S. Y. (2010) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2010.01.001 · Cited by 26

Innovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines

Manabe, Y., & Fukase, K. (2023) · Methods in Molecular Biology · doi:10.1007/978-1-0716-2910-9_5 · Cited by 5